menu search

Protara therapeutics announces third quarter 2023 financial results and business update

dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preli...

November 3, 2023, 12:00 pm

Kura oncology and mirati therapeutics enter into clinical collaboration and supply agreement to evaluate ko-2806 and adagrasib in krasᴳ¹²ᶜ-mutated nsclc

– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in com...

November 2, 2023, 11:30 am

Acumen pharmaceuticals presents late-breaker phase 1 updates exploring novel target engagement, dosing regimen and safety findings for acu193 in early alzheimer’s disease at the 16th annual clinical t

– Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to...

October 27, 2023, 1:25 pm

Kronos bio presents positive preliminary data from phase 1 dose escalation portion of phase 1/2 kb-0742 study at aacr-nci-eortc

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manage...

October 13, 2023, 4:30 pm

Oxford cannabinoid readies for next stage as it safely navigates phase i stduy

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) hailed as a 'major milestone' the successful completion of ...

October 10, 2023, 2:22 am

Eagle pharmaceuticals awarded first prize for poster to be presented at the international society for anaesthetic pharmacology 32nd annual meeting

— Study reports on an interim analysis of the pharmacokinetics and pharmacodynamics of remimazolam and a subsequent model-based optimization of the ...

October 4, 2023, 10:50 am

Why is gain therapeutics (ganx) stock moving today?

Gain Therapeutics (NASDAQ: GANX ) stock is on the move Wednesday as investors react to updated clinical trial news from the company. According to a p...

October 4, 2023, 8:45 am

Structure therapeutics stock soars on positive weight loss data

Structure Therapeutics Inc shares surged 34% to $50.34 in midday trading on Friday after the clinical-stage global biopharmaceutical company announced...

September 29, 2023, 12:55 pm

Roivant announces positive initial imvt-1402 phase 1 sad and 300 mg subcutaneous mad results

IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab No dec...

September 26, 2023, 10:00 am

Immunovant announces positive initial imvt-1402 phase 1 sad and 300 mg subcutaneous mad results

IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab No dec...

September 26, 2023, 10:00 am

Why shares of ars pharmaceuticals are plummeting on wednesday

ARS Pharmaceutical is seeking the approval of Neffy, a nasal spray version of epinephrine. The FDA is seeking additional ...

September 20, 2023, 12:42 pm

Harpoon therapeutics announces first patients with small cell lung cancer dosed in hpn328 combination cohort

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company d...

September 15, 2023, 11:15 am

Altimmune (alt) rises 7% on completing dosing in obesity study

Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The...

September 13, 2023, 9:01 am

Curevac signals progress on mrna flu vaccine

CureVac NV CVAC, -3.85% said Tuesday that it has selected an mRNA flu vaccine candidate for continued clinical development, based on positive results ...

September 12, 2023, 8:05 am

Oxford cannabinoid technologies hails defining year as clinical trials remain on track

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) hailed a “defining year” for the progress of its leading drug candidates and ...

August 31, 2023, 2:55 am

Apogee therapeutics: potential to target autoimmune disorders with less frequent dosing

Review of Apogee Therapeutics' safety and pharmacokinetic data from phase 1 study using APG777 in healthy volunteers expected in mid-2024. Pending pos...

August 22, 2023, 8:14 am

Phio pharmaceuticals announces dosing of first patient in collaborative clinical trial with agonox, inc. and providence cancer institute

Trial targeting treatment of metastatic melanoma and other solid tumors MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Co...

August 21, 2023, 11:30 am

Eylea hd (aflibercept) injection 8 mg approved by fda for treatment of wet age-related macular degeneration (wamd), diabetic macular edema (dme) and diabetic retinopathy (dr)

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Inje...

August 18, 2023, 10:35 pm

Processa pharmaceuticals provides data update supporting a potential personalized treatment approach for improved cancer care

Interim analysis of Phase 1B data suggests Processa’s novel chemotherapy treatment could improve safety and efficacy in more patients by individuali...

August 17, 2023, 12:05 pm

Eyenovia acquires u.s. commercial rights to app13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) from formosa pharmaceuticals

APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while redu...

August 16, 2023, 10:00 am


Search within

Pages Search Results: